Skip to main
ARDT

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Ardent Health Inc. demonstrated strong financial performance with an EBITDA of $143 million, reflecting a 46% year-over-year increase and an improved margin of 9.1%, up by 240 basis points. The company experienced a 2.9% growth in admissions, aligning with its full-year outlook, while professional fees rose significantly by 11% in the most recent quarter, indicating continued investment in critical services such as anesthesia and radiology. Furthermore, Ardent's strategic focus on outpatient services and the positive trends within the hospital sector suggest substantial growth potential, positioning the company to capitalize on its under-earning capacity.

Bears say

Ardent Health's stock outlook is negatively impacted by a lower-than-expected underlying EBITDA performance, which was bolstered by one-time gains from Kansas SDPs, overshadowing ongoing revenue challenges. The company’s transition to the Kodiak revenue cycle management platform has resulted in a significant $43 million revenue adjustment, contributing to a conservative outlook on accounts receivable collectability and diminished growth expectations. Additionally, revised EBITDA-NCI estimates reflect a downward adjustment to $542 million for 2025 and $536 million for 2026, representing a combined reduction of approximately 9% in 2025 guidance, underscoring concerns about minimal to negative EBITDA growth moving forward.

ARDT has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 12 analysts, ARDT has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.